Synexus is looking to register 30,000 adults for a five-year study with the goal of identifying potential prevention methods and possible treatments for Alzheimer’s disease and other dementias.
Synexus has been bought by its management in a private equity backed deal that sees Lyceum Capital relinquish control of the trial recruitment specialist.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at PharmaNet, Synexus, KCAS, Catalent and CIS.
Outsourcing-pharma presents a round up of all the latest deals and developments in the contract research space. This week Synexus closes ClinPharm deal, GVK joins ResearchPoint Global and CliniPace wins gNO contract.
Synexus has agreed to acquire Clinpharm, giving it access to 10 clinical trial sites in Germany, Austria and Ukraine and increasing its patient population reach in Europe by 100 per cent.
Synexus has recruited more than 2,000 children in three months for a Phase III rotavirus vaccine study, which it believes validates its methods and demonstrates they are particularly effective in late stage vaccine trials.
Synexus is meeting the rising demand for its services, which it says can dramatically increase recruitment rates, by acquiring clinical trial sites in Poland and is hoping to expand in India soon.
Synexus has been making business strides of late, thanks to its
"innovative" model for patient recruitment and monitoring
for late stage clinical trials.
Management of publicly-traded Synexus have agreed to the £18.1m
(€25.7m) sale of the company to a private equity firm that has
promised to fund its global expansion ventures.
UK-based Synexus Clinical Research is continuing its global
movements with the latest acquisition of South African outfit
Clinical Research Centers (CRC).
